KIT and neoplasm: A randomised, Phase 3 clinical trial of masitinib demonstrated it was effective at delaying tumour progression in dogs with recurrent or non-resectable grade II-III non-metastatic MCT (increased OS from 75 to 253 days), with the presence of KIT mutations showing an improved response [113].